IRF1 and neoplasm: IRF1 has been shown to upregulate CD274 (that encodes PD-L1) expression in the tumor microenvironment and IRF1 “knock-out” has been shown to render tumor cells more susceptible to CD8+ T cell-mediated killing [32,33].